Cancer Cardio Oncology Risk Factors 
DAIC
JUNE 19, 2024
Getty Images milla1cf Wed, 06/19/2024 - 20:54 June 19, 2024 — Modern therapies have extended the lives of many cancer patients; however, survivors often live with chronic health conditions, including cardiovascular disease. The new study was motivated by a need to fill that gap, Rao said. They found that exposure to PM2.5,
DAIC
FEBRUARY 28, 2024
The findings – published this week in the Journal of the American College of Cardiology — could fuel advocacy for a paradigm shift in clinical heart health guidelines to address cardiovascular risk factors at an earlier age in childhood cancer survivors. “We Wendy Bottinor, MD.
Frontiers in Cardiovascular Medicine
JANUARY 19, 2024
Background Cancer therapy-related cardiac dysfunction due to trastuzumab has been well-known for many years, and echocardiographic surveillance is recommended every 3 months in patients undergoing trastuzumab treatment, irrespective of the baseline cardiotoxicity risk. Results Twelve (10.9%) patients had asymptomatic CTRCD.
Heart BMJ
NOVEMBER 27, 2023
The number of patients at the intersection of cancer and cardiovascular disease (CVD) is increasing, reflecting ageing global populations, rising burden of shared cardiometabolic risk factors, and improved cancer survival. Many cancer treatments carry a risk of cardiotoxicity.
Open Heart
AUGUST 22, 2022
Objective Adjuvant chemotherapy with trastuzumab improves the postoperative life expectancy of women with early-stage breast cancer. Women with breast cancer who underwent initial surgery were included. Although trastuzumab is reportedly cardiotoxic, quantification based on real-world evidence is lacking.
Expert insights. Personalized for you.
111 
Let's personalize your content